相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Correlates of Fatigability in Patients With Spinal Muscular Atrophy
Bart Bartels et al.
NEUROLOGY (2021)
Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors
Jeffrey Aldrich et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies
Elia Sechi et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Neuro-Ophthalmic Complications in Patients Treated With CTLA-4 and PD-1/PD-L1 Checkpoint Blockade
Michel M. Sun et al.
JOURNAL OF NEURO-OPHTHALMOLOGY (2021)
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Divyanshu Dubey et al.
ANNALS OF NEUROLOGY (2020)
Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry
Rik J. Verheijden et al.
CLINICAL CANCER RESEARCH (2020)
CRMP5-IgG-Associated Paraneoplastic Myelopathy With PD-L1 Inhibitor Therapy
Amy Kunchok et al.
JAMA NEUROLOGY (2020)
Neuromyelitis optica spectrum disorder after treatment with pembrolizumab
Tomoyo Shimada et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Worsening of anti-Hu paraneoplastic neurological syndrome related to anti-PD-1 treatment: Case report and review of literature
Pooja Raibagkar et al.
JOURNAL OF NEUROIMMUNOLOGY (2020)
Central nervous system complications associated with immune checkpoint inhibitors
Alberto Vogrig et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)
Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials
Jordi Bruna et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2020)
Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients
Stefania Cuzzubbo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Neurologic autoimmunity and immune checkpoint inhibitors
Elia Sechi et al.
NEUROLOGY (2020)
HLA-B27 association of autoimmune encephalitis induced by PD-L1 inhibitor
Hyeyeon Chang et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2020)
Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy
Shahar Shelly et al.
BRAIN COMMUNICATIONS (2020)
Is neuromyelitis optica without AQP4-IgG a T-cell mediated disease? insights from checkpoint inhibitor immune-related adverse events
Salam Nasralla et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Autoimmune encephalitis associated with Ma2 antibodies and immune checkpoint inhibitor therapy
Shane Lyons et al.
PRACTICAL NEUROLOGY (2020)
Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1
Andrew L. Mammen et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer
Kenneth L. Kehl et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Multiple sclerosis outcomes after cancer immunotherapy
Catherine R. Garcia et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2019)
Management of Immunotherapy-Related Toxicities. Version 1.2019
John A. Thompson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies Systematic review
Annette Johansen et al.
NEUROLOGY (2019)
Paraneoplastic autoimmunity and small-cell lung cancer: Neurological and serological accompaniments
Anastasia Zekeridou et al.
THORACIC CANCER (2019)
Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy
Xi Chen et al.
CLINICAL NEUROPHYSIOLOGY (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
Douglas B. Johnson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Myocarditis in the Setting of Cancer Therapeutics Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology
Marc P. Bonaca et al.
CIRCULATION (2019)
Encephalitis induced by immune checkpoint inhibitors in metastatic melanoma: a monocentric retrospective study
S. Galmiche et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors
Laura C. Kennedy et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis
Douglas B. Johnson et al.
NATURE MEDICINE (2019)
Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy
Khashayar Esfahani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis
Joe-Elie Salem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer
Audrey Simonaggio et al.
JAMA ONCOLOGY (2019)
A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes
Alexander J. Gill et al.
JOURNAL OF NEUROIMMUNOLOGY (2019)
Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies
Divyanshu Dubey et al.
NEUROLOGY (2019)
Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab
N. Shah et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors
Alberto Vogrig et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2019)
Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database
Kenichiro Sato et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature
Houssein Safa et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature
Marcela Carausu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study
J. von Pawel et al.
EUROPEAN JOURNAL OF CANCER (2019)
Immune checkpoint inhibitor induced anti-glutamic acid decarboxylase 65 (Anti-GAD 65) limbic encephalitis responsive to intravenous immunoglobulin and plasma exchange
Matthew Chung et al.
JOURNAL OF NEUROLOGY (2019)
Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy
Karen Bitton et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2019)
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
Guillaume Manson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Posterior reversible encephalopathy syndrome induced by nivolumab immunotherapy for non-small-cell lung cancer
Dohhyung Kim
CLINICAL CASE REPORTS (2019)
A rare case of Miller Fisher variant of Guillain-Barre Syndrome (GBS) induced by a checkpoint inhibitor
Caitlin Jane McNeill et al.
BMJ CASE REPORTS (2019)
How we treat neurological toxicity from immune checkpoint inhibitors
Lavinia Spain et al.
ESMO OPEN (2019)
Lambert-Eaton Myasthenic Syndrome Secondary to Nivolumab and Ipilimumab in a Patient with Small-Cell Lung Cancer
Kavita Agrawal et al.
CASE REPORTS IN NEUROLOGICAL MEDICINE (2019)
Anti-Hu-Associated Autoimmune Limbic Encephalitis in a Patient with PD-1 Inhibitor-Responsive Myxoid Chondrosarcoma
Kyriakos P. Papadopoulos et al.
ONCOLOGIST (2018)
Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease A Systematic Review
Noha Abdel-Wahab et al.
ANNALS OF INTERNAL MEDICINE (2018)
Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report
Yoshitsugu Narumi et al.
BMC CANCER (2018)
Nivolumab-induced Limbic Encephalitis with Anti-Hu Antibody in a Patient With Advanced Pleomorphic Carcinoma of the Lung
Hiroki Matsuoka et al.
CLINICAL LUNG CANCER (2018)
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders
Giulia C. Leonardi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Neurologic complications of immune checkpoint inhibitors
Avi Fellner et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Severe neurologic complications of immune checkpoint inhibitors: a single-center review
Sarah Mancone et al.
JOURNAL OF NEUROLOGY (2018)
Acute cerebellitis after administration of nivolumab and ipilimumab for small cell lung cancer
Tatsuhiko Naito et al.
NEUROLOGICAL SCIENCES (2018)
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
M. R. Migden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
Fernando C. Santini et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Seronegative antibody-mediated neurology after immune checkpoint inhibitors
Robert Wilson et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2018)
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Kathryn C. Arbour et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer
Mehdi Touat et al.
NEUROLOGY (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A case of severe encephalitis while on PD-1 immunotherapy for recurrent clear cell ovarian cancer
Morgan Burke et al.
GYNECOLOGIC ONCOLOGY REPORTS (2018)
Natalizumab may control immune checkpoint inhibitor-induced limbic encephalitis
Andreas F. Hottinger et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2018)
Lambert-Eaton Myasthenic Syndrome Caused by Nivolumab in a Patient with Squamous Cell Lung Cancer
Yuki Nakatani et al.
CASE REPORTS IN NEUROLOGY (2018)
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
M. H. Pollack et al.
ANNALS OF ONCOLOGY (2018)
Nivolumab-Induced Autoimmune Encephalitis in Two Patients with Lung Adenocarcinoma
Suma Shah et al.
CASE REPORTS IN NEUROLOGICAL MEDICINE (2018)
Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature
L. Spain et al.
ANNALS OF ONCOLOGY (2017)
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
J. C. Osorio et al.
ANNALS OF ONCOLOGY (2017)
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
A. M. Menzies et al.
ANNALS OF ONCOLOGY (2017)
Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
S. Cuzzubbo et al.
EUROPEAN JOURNAL OF CANCER (2017)
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
Hans J. Hammers et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
Robert Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy
Michael P. Brown et al.
JOURNAL OF NEUROIMMUNOLOGY (2017)
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Padmanee Sharma et al.
LANCET ONCOLOGY (2017)
Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody
Jo Raskin et al.
LUNG CANCER (2017)
Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives
Lidia M. Yshii et al.
NATURE REVIEWS NEUROLOGY (2017)
Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan
Shigeaki Suzuki et al.
NEUROLOGY (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic Melanoma
Simon Bossart et al.
ONCOLOGIST (2017)
Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies
Justin C. Kao et al.
JAMA NEUROLOGY (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events
Marianne Davies et al.
IMMUNOTARGETS AND THERAPY (2017)
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study
A. Necchi et al.
ANNALS OF ONCOLOGY (2017)
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
S. Champiat et al.
ANNALS OF ONCOLOGY (2016)
CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis
Lisa Ann Gerdes et al.
ANNALS OF NEUROLOGY (2016)
CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model
Lidia M. Yshii et al.
BRAIN (2016)
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
Lisa Zimmer et al.
EUROPEAN JOURNAL OF CANCER (2016)
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
Christophe Massard et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman et al.
LANCET ONCOLOGY (2016)
CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment
Yonghao Cao et al.
NEUROLOGY (2016)
Frequency of Synaptic Autoantibody Accompaniments and Neurological Manifestations of Thymoma
Anastasia Zekeridou et al.
JAMA NEUROLOGY (2016)
Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer
Tanya J. Williams et al.
JAMA NEUROLOGY (2016)
Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma
Leila Khoja et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B. Johnson et al.
JAMA ONCOLOGY (2016)
New-Onset Mediastinal and Central Nervous System Sarcoidosis in a Patient with Metastatic Melanoma Undergoing CTLA4 Monoclonal Antibody Treatment
Kevin P. Murphy et al.
Oncology Research and Treatment (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Troy Z. Horvat et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Vogt-Koyanagi-Harada-like Syndrome After CTLA-4 Inhibition With Ipilimumab for Metastatic Melanoma
Jason N. Crosson et al.
JOURNAL OF IMMUNOTHERAPY (2015)
Anti-Ma-associated encephalomyeloradiculopathy in a patient with pleural mesothelioma
Alberto Vogrig et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma
Edward J. Gettings et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)
D. McDermott et al.
ANNALS OF ONCOLOGY (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies A beneficial antitumor immune response going awry
Beatrice S. L. Pignolet et al.
ONCOIMMUNOLOGY (2013)
Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant Melanoma
Michela Maur et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Accelerated Course of Experimental Autoimmune Encephalomyelitis in PD-1-Deficient Central Nervous System Myelin Mutants
Antje Kroner et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Recommended diagnostic criteria for paraneoplastic neurological syndromes
F Graus et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2004)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
分享论文
